Skip to main content
ONCIMMUNE HOLDINGS PLC logo

ONCIMMUNE HOLDINGS PLC — Investor Relations & Filings

Ticker · ONC ISIN · GB00BYQ94H38 LEI · 213800HCYIWT6YPI1I02 IL Professional, scientific and technical activities
Open in API
Filings indexed 362 across all filing types
Latest filing 2020-08-07 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL ONC

About ONCIMMUNE HOLDINGS PLC

https://www.oncimmune.com/

Oncimmune Holdings PLC is a precision medicine and immunodiagnostics company specializing in the discovery and application of antibody and autoantibody biomarker signatures. The company's core technology is the ImmunoINSIGHTS™ platform, an advanced analytical engine for immune profiling. This platform utilizes a proprietary library of over 9,000 human antigens, bead-based multiplexed immunoassay technology, and machine learning algorithms to generate biological insights from minimal sample volumes. Oncimmune applies its expertise across therapeutic areas including immuno-oncology, autoimmune diseases, and infectious diseases. It provides biomarker discovery services, targeted panels, and advanced bioinformatics to support pharmaceutical and biotechnology partners in developing more effective and targeted treatments and diagnostics.

Recent filings

Filing Released Lang Actions
Exercise of Options and Total Voting Rights
Share Issue/Capital Change Classification · 99% confidence The document begins with an 'RNS Number' and is dated August 7, 2020. The content announces the 'Exercise of Options & Total Voting Rights' and the subsequent admission of new ordinary shares to trading on AIM. This type of announcement, which details changes in the total number of voting rights following an event (like option exercise or share issuance) and is distributed via the RNS system, is a specific corporate action notification. While it relates to share capital changes (SHA) or insider transactions (DIRS), the primary function here is a regulatory disclosure about the total share count denominator required by the FCA's Disclosure and Transparency Rules. Since it is a general regulatory announcement distributed via RNS that doesn't fit perfectly into the more specific categories like DIV, SHA, or DIRS (as it's not a buyback or a director's trade, but a consequence of an option exercise affecting the total share count), the most appropriate general regulatory filing category is RNS, as it is explicitly branded as an RNS release and serves as a general regulatory update.
2020-08-07 English
Further evidence for the use of the EarlyCDT Lung
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and the issuer 'Oncimmune Holdings PLC', indicating it is a regulatory announcement filed via the London Stock Exchange's Regulatory News Service (RNS). The content describes the presentation of two abstracts related to the EarlyCDT Lung blood test and the ECLS trial, including details about cost-effectiveness and psychological impact. This is an announcement updating investors on recent scientific/trial developments and presentations, rather than a full financial report (10-K, IR) or a formal earnings release (ER). Since it is a general regulatory update disseminated through RNS that doesn't fit specific categories like DIV, MANG, or DIRS, the most appropriate classification is the general regulatory filing category.
2020-08-05 English
ERJ publishes results from the ECLS study
Legal Proceedings Report Classification · 99% confidence The document begins with 'RNS Number : 6794U' and is dated July 31, 2020. It announces that the European Respiratory Journal has published peer-reviewed results from the ECLS study concerning the company's EarlyCDT Lung test. This is a formal announcement disseminated through a regulatory news service (RNS) regarding a significant development (publication of clinical trial results) that is not a full financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV). Since it is a general, material announcement distributed via the RNS system, and it doesn't fit neatly into the other specific categories (like ER, CT, or IP), the most appropriate classification is the general regulatory announcement category, RNS.
2020-07-31 English
Roche Contract Expansion to Profile Autoantibodies
Earnings Release Classification · 99% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's Regulatory Information Service (RNS). The content details a business update: the expansion of a contract with Roche regarding profiling autoantibodies. This is a material event announcement concerning business operations and contract value, not a full financial report (like 10-K or IR), a formal proxy statement (DEF 14A), or a transcript (CT). Since it is a general regulatory announcement disseminated through RNS that doesn't fit perfectly into specific categories like Director's Dealing (DIRS) or Capital Change (CAP), the most appropriate classification is the general regulatory filing category, RNS. FY 2020
2020-07-27 English
Exercise of Options and Total Voting Rights
Share Issue/Capital Change Classification · 99% confidence The document is clearly identified as an 'RNS Number' filing from 'Oncimmune Holdings PLC' dated '24 July 2020'. The content announces the 'Exercise of Options & Total Voting Rights' and the subsequent admission of new shares to trading on AIM. This type of announcement, which details changes in share capital, insider transactions (via option exercise), and updates the total voting rights denominator for regulatory compliance (FCA's Disclosure and Transparency Rules), fits best under categories related to share changes or general regulatory updates. Since it specifically details the issuance of new shares following an option exercise, it strongly aligns with 'Share Issue/Capital Change' (SHA). However, the document is formatted as a standard regulatory news service release (RNS) and deals with a specific corporate action (share issuance/voting rights update). Given the options, 'SHA' (Share Issue/Capital Change) is the most precise fit for the core subject matter (new shares admitted to trading). If SHA were not available, RNS would be the fallback, but SHA is more specific here.
2020-07-24 English
Paper highlights potential of ImmunoINSIGHTS in RA
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 3039S' and is dated '08 July 2020'. The content describes Oncimmune Holdings PLC noting the publication of a research paper supported by its ImmunoINSIGHTS team in 'Arthritis Research & Therapy'. This is an announcement about external research findings relevant to the company's technology, not a primary financial filing like a 10-K, IR, or ER. The structure, use of RNS numbering, and the nature of the announcement (notifying the market of positive news/publication) strongly indicate this is a general regulatory announcement disseminated via the London Stock Exchange's news service. Since it is a general regulatory announcement that doesn't fit the specific categories like DIRS, DIV, or MANG, the most appropriate fallback category is Regulatory Filings (RNS). The document length (7038 chars) is substantial enough that it is not merely an RPA announcing a report, but the report itself is external (a journal publication).
2020-07-08 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.